New Enterprise Associates Healthcare News

This is selected healthcare news for New Enterprise Associates, which is filed under Capital Firms. There are 373 news items for this page. New Enterprise Associates is occasionally combined with Aetion, Biotechnology Innovation Organization and Bioelectronic Medicine in news items. A press release filter page is also available for New Enterprise Associates.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/2/2022 San Diego biotech Escient Pharmaceuticals pulls in $120M to pursue novel drug candidates
... to clinical proof-of-concept in multiple indications,‚Au said Chief Executive Joshua Grass in a statement. The financing, announced Monday, was co-led by New Enterprise Associates, Abingworth and Forge Life Science Partners with additional new investors Avego, PFM Health Sciences and The Eleven Fund participating. Existing investors ...
sandiegouniontribune.com
11/29/2022 2022-11-29 | NDAQ:LUMO | Press Release | Lumos Pharma Inc.
... rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Sant√© Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule ...
stockhouse.com
11/29/2022 Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2
... rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently ...
Globe Newswire
11/29/2022 Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
... rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently ...
Yahoo News
11/28/2022 Escient Pharmaceuticals Announces $120 Million Series C Financing
Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and EP547 to multiple clinical milestones SAN DIEGO, November 28, 2022 --( BUSINESS WIRE )--Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range ...
Yahoo News
11/28/2022 Daily Deal Round Up: November 28, 2022
... C round while Castrol India provided $60m for Ki Mobility Solutions. Funding Company nameCompany descriptionSectorCountryRoundRound size($m)Deal dateInvestorsEscient PharmaceuticalsNeurosensory therapeutic treatment developerHealthcareUSC12028/11/2022Sanofi (Sanofi Ventures); New Enterprise Associates (co-lead), Abingworth (co-lead), Forge Life Science Partners (co-lead), Cowen (Cowen Healthcare Investments), Avego, PFM Health Sciences, Eleven (The Eleven ...
globalventuring.com
11/27/2022 Escient Pharmaceuticals Announces $120 Million Series C Financing
Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners - Proceeds support advancement of EP262 and EP547 to multiple clinical milestones SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory ...
acrofan.com
11/23/2022 Scoop: Versant, NEA launch new biotech helmed by ex-CEO of protein degrader C4 Therapeutics – Endpoints News
Long-time biotech venture firms Versant and New Enterprise Associates are backing a new startup run by former C4 Therapeutics chief executive Andrew Phillips . The fledgling biotech has raised at least $30 million so far, according to paperwork filed with the SEC this week. The round could balloon to $60 ...
endpts.com
11/19/2022 ReCode Therapeutics Announces Scientific Advisory Board, New Scientific Adviser
... Sigal, M.D., Ph.D., the newest scientific adviser, serves as co-chair of the scientific advisory board for Amgen Inc. and as a senior advisor to New Enterprise Associates, Inc. He's a member of the board of directors for Adaptimmune Therapeutics, Vir Biotechnology, Surface Oncology, Tessera Therapeutics, and Affinia Therapeutics ...
dallasinnovates.com
11/15/2022 Affordability Education Gap Is No. 1 Barrier to Increasing Independent and Gig Worker Health Coverage Rate, Per New Stride Health Survey
... provide their workers with access to a full marketplace of health and wealth benefits. The company is backed by $96 million in capital from Venrock, New Enterprise Associates, Fidelity's F-Prime Capital Partners, Mastercard, Allstate and King River . For more information, visit https://www.stridehealth.com . SOURCE Stride Health ...
PR Newswire
11/15/2022 Nearly 1 in 4 gig workers lacks health insurance, survey finds
... said Noah Lang, CEO and co-founder of Stride. Founded in 2013, San Francisco-based Stride is backed by $96 million in capital from Venrock, New Enterprise Associates, Fidelity's F-Prime Capital Partners, Mastercard, Allstate and King River ...
Healthcare Dive
11/15/2022 Nearly 1 in 4 gig workers lacks health insurance, survey finds - Healthcare Dive - News07trends
... said Noah Lang, CEO and co-founder of Stride. Founded in 2013, San Francisco-based Stride is backed by $96 million in capital from Venrock, New Enterprise Associates, Fidelity's F-Prime Capital Partners, Mastercard, Allstate and King River. Follow more to update News07trends Most Related Links : News07trends Business News ...
universalpersonality.com
11/14/2022 MBX Biosciences Closes $115 Million Series B Financing to
... Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board. ‚AuMBX has ...
Globe Newswire
11/14/2022 MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
... Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board. ‚AuMBX has ...
forextv.com
11/14/2022 MBX Biosciences closes on $115M in drug-development funding – Indianapolis Business Journal
... Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners, along with existing investors Frazier Life Sciences, New Enterprise Associates and OrbiMed. ‚AuThis latest raise really will help us achieve our mission of pioneering precision endocrine peptides and help people with endocrine ...
ibj.com
11/14/2022 MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
... Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board. ‚AuMBX has ...
biotechwinners.com
11/14/2022 Lumos Pharma Announces Encouraging Interim Results from Two
... rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently ...
Globe Newswire
11/14/2022 Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
... rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently ...
Yahoo News
11/14/2022 Lumos Pharma Reports Third Quarter 2022 Financial Results
... rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently ...
Globe Newswire
11/14/2022 ReCode Therapeutics Establishes Scientific Advisory Board
... Elliott Sigal, M.D., Ph.D. Dr. Sigal currently serves as co-chair of the scientific advisory board for Amgen, Inc. and as a senior advisor to New Enterprise Associates, Inc. He is a member of the Board of Directors for Adaptimmune Therapeutics, Vir Biotechnology, Surface Oncology, Tessera Therapeutics and Affinia Therapeutics ...
Business Wire
11/14/2022 2022-11-14 | NDAQ:LUMO | Press Release | Lumos Pharma Inc.
... rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Sant√© Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule ...
stockhouse.com
11/7/2022 Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022 | Business | fbherald.com
... minority interest in the company and has an exclusive option to acquire Pionyr upon completion of certain Phase 1b studies. Pionyr's additional investors include New Enterprise Associates, OrbiMed, SV Health Investors, Sofinnova Ventures, Vida Ventures, Osage University Partners, Mission Bay Capital, and Trinitas Ventures. For more information, please visit ...
Business Wire
11/7/2022 Pionyr Immunotherapeutics' MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022 - Business Wire
... minority interest in the company and has an exclusive option to acquire Pionyr upon completion of certain Phase 1b studies. Pionyr's additional investors include New Enterprise Associates, OrbiMed, SV Health Investors, Sofinnova Ventures, Vida Ventures, Osage University Partners, Mission Bay Capital, and Trinitas Ventures. For more information, please visit ...
Business Wire
11/4/2022 PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
... all the best in his current and future endeavors.‚Au Dr. Gallagher is a veteran Board director and currently serves as a venture partner at New Enterprise Associates (NEA), a global venture capital firm. Over the last ten years she has served as a director at multiple public and private ...
Yahoo News
11/4/2022 PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol
... all the best in his current and future endeavors.‚Au Dr. Gallagher is a veteran Board director and currently serves as a venture partner at New Enterprise Associates (NEA), a global venture capital firm. Over the last ten years she has served as a director at multiple public and private ...
Globe Newswire